– моментальные уведомления о рынке акций
– моментальные уведомления о рынке акций
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 2, 2022.
First Quarter 2022 Highlights
“We are very pleased to deliver another quarter of excellent performance,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We started the year with great momentum, executing our proven growth strategy and continuing to be a trusted partner for our customers. Our PPD clinical research business is performing very well, the integration is going smoothly and we are even more excited about the opportunities we have to further enable the success of our pharma and biotech customers.”
Casper added, “The strong execution by our team in the first quarter positions us to deliver another outstanding year.”
First Quarter 2022
Revenue for the quarter grew 19% to $11.82 billion in 2022. Organic revenue growth was 3%, acquisitions increased revenue by 18% and currency translation decreased revenue by 2%. Core organic growth was 16%. COVID-19 testing revenue was $1.68 billion.
GAAP Earnings Results
GAAP diluted EPS in the first quarter of 2022 was $5.61, versus $5.88 in the same quarter last year. GAAP operating income for the first quarter of 2022 was $2.82 billion, compared with $3.05 billion in the year-ago quarter. GAAP operating margin was 23.9%, compared with 30.8% in the first quarter of 2021.
Non-GAAP Earnings Results
Adjusted EPS in the first quarter of 2022 was $7.25, versus $7.21 in the first quarter of 2021. Adjusted operating income for the first quarter of 2022 was $3.45 billion, compared with $3.51 billion in the first quarter of 2021. Adjusted operating margin was 29.2%, compared with 35.4% in the first quarter of 2021.
Annual Guidance for 2022
The company will provide updated 2022 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Daylight Time.
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading "Supplemental Information Regarding Non-GAAP Financial Measures." The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today, April 28, at 8:30 a.m. Eastern Daylight Time. To listen, dial (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The access code is 310385. You may also listen to the call live on our website, www.thermofisher.com, by clicking on “Investors.” You will find this press release, including the accompanying reconciliation of non-GAAP financial measures and related information, in that section of our website under “Financials.” An audio archive of the call will be available under “News and Events” through Friday, May 13, 2022.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Condensed Consolidated Statement of Income (unaudited) |
||||||||||||||
|
|
Three months ended |
||||||||||||
|
|
April 2, |
|
% of |
|
April 3, |
|
% of |
||||||
(In millions except per share amounts) |
|
2022 |
|
Revenues |
|
2021 |
|
Revenues |
||||||
Revenues |
|
$ |
11,818 |
|
|
|
|
$ |
9,906 |
|
|
|
||
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
Cost of revenues (a) |
|
|
6,214 |
|
|
52.6 |
% |
|
|
4,557 |
|
|
46.0 |
% |
Selling, general and administrative expenses (b) |
|
|
1,808 |
|
|
15.3 |
% |
|
|
1,543 |
|
|
15.6 |
% |
Amortization of acquisition-related intangible assets |
|
|
609 |
|
|
5.2 |
% |
|
|
423 |
|
|
4.3 |
% |
Research and development expenses |
|
|
364 |
|
|
3.1 |
% |
|
|
320 |
|
|
3.2 |
% |
Restructuring and other costs (c) |
|
|
2 |
|
|
0.0 |
% |
|
|
14 |
|
|
0.1 |
% |
|
|
|
8,997 |
|
|
76.1 |
% |
|
|
6,857 |
|
|
69.2 |
% |
Operating income |
|
|
2,821 |
|
|
23.9 |
% |
|
|
3,049 |
|
|
30.8 |
% |
Interest income |
|
|
18 |
|
|
|
|
|
12 |
|
|
|
||
Interest expense |
|
|
(136 |
) |
|
|
|
|
(125 |
) |
|
|
||
Other income/(expense) (d) |
|
|
(163 |
) |
|
|
|
|
(183 |
) |
|
|
||
Income before income taxes |
|
|
2,540 |
|
|
|
|
|
2,753 |
|
|
|
||
Provision for income taxes (e) |
|
|
(301 |
) |
|
|
|
|
(416 |
) |
|
|
||
Equity in earnings/(losses) of unconsolidated entities |
|
|
(19 |
) |
|
|
|
|
— |
|
|
|
||
Net income |
|
|
2,220 |
|
|
|
|
|
2,337 |
|
|
|
||
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
5 |
|
|
|
|
|
— |
|
|
|
||
Net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
2,215 |
|
|
18.7 |
% |
|
$ |
2,337 |
|
|
23.6 |
% |
|
|
|
|
|
|
|
|
|
||||||
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
$ |
5.66 |
|
|
|
|
$ |
5.93 |
|
|
|
||
Diluted |
|
$ |
5.61 |
|
|
|
|
$ |
5.88 |
|
|
|
||
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
|
392 |
|
|
|
|
|
394 |
|
|
|
||
Diluted |
|
|
395 |
|
|
|
|
|
397 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
GAAP operating income |
|
$ |
2,821 |
|
|
23.9 |
% |
|
$ |
3,049 |
|
|
30.8 |
% |
Cost of revenues adjustments (a) |
|
|
11 |
|
|
0.1 |
% |
|
|
8 |
|
|
0.1 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
7 |
|
|
0.0 |
% |
|
|
16 |
|
|
0.1 |
% |
Restructuring and other costs (c) |
|
|
2 |
|
|
0.0 |
% |
|
|
14 |
|
|
0.1 |
% |
Amortization of acquisition-related intangible assets |
|
|
609 |
|
|
5.2 |
% |
|
|
423 |
|
|
4.3 |
% |
Adjusted operating income (non-GAAP measure) |
|
$ |
3,450 |
|
|
29.2 |
% |
|
$ |
3,510 |
|
|
35.4 |
% |
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
GAAP net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
2,215 |
|
|
|
|
$ |
2,337 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
11 |
|
|
|
|
|
8 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
7 |
|
|
|
|
|
16 |
|
|
|
||
Restructuring and other costs (c) |
|
|
2 |
|
|
|
|
|
14 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
609 |
|
|
|
|
|
423 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
167 |
|
|
|
|
|
197 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
(169 |
) |
|
|
|
|
(130 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
19 |
|
|
|
|
|
— |
|
|
|
||
Adjusted net income (non-GAAP measure) |
|
$ |
2,861 |
|
|
|
|
$ |
2,865 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
|
$ |
5.61 |
|
|
|
|
$ |
5.88 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
0.03 |
|
|
|
|
|
0.02 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
0.02 |
|
|
|
|
|
0.04 |
|
|
|
||
Restructuring and other costs (c) |
|
|
0.01 |
|
|
|
|
|
0.04 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
1.54 |
|
|
|
|
|
1.06 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
0.42 |
|
|
|
|
|
0.50 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
(0.43 |
) |
|
|
|
|
(0.33 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
0.05 |
|
|
|
|
|
0.00 |
|
|
|
||
Adjusted EPS (non-GAAP measure) |
|
$ |
7.25 |
|
|
|
|
$ |
7.21 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
|
||||||
GAAP net cash provided by operating activities |
|
$ |
2,202 |
|
|
|
|
$ |
1,978 |
|
|
|
||
Purchases of property, plant and equipment |
|
|
(640 |
) |
|
|
|
|
(628 |
) |
|
|
||
Proceeds from sale of property, plant and equipment |
|
|
2 |
|
|
|
|
|
5 |
|
|
|
||
Free cash flow (non-GAAP measure) |
|
$ |
1,564 |
|
|
|
|
$ |
1,355 |
|
|
|
||
Segment data |
|
Three months ended |
||||||||||||
|
|
April 2, |
|
% of |
|
April 3, |
|
% of |
||||||
(In millions) |
|
2022 |
|
Revenues |
|
2021 |
|
Revenues |
||||||
|
|
|
|
|
|
|
|
|
||||||
Revenues |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
4,231 |
|
|
35.8 |
% |
|
$ |
4,203 |
|
|
42.4 |
% |
Analytical Instruments |
|
|
1,518 |
|
|
12.8 |
% |
|
|
1,387 |
|
|
14.0 |
% |
Specialty Diagnostics |
|
|
1,482 |
|
|
12.5 |
% |
|
|
1,615 |
|
|
16.3 |
% |
Laboratory Products and Biopharma Services |
|
|
5,442 |
|
|
46.0 |
% |
|
|
3,597 |
|
|
36.3 |
% |
Eliminations |
|
|
(855 |
) |
|
-7.1 |
% |
|
|
(896 |
) |
|
-9.0 |
% |
Consolidated revenues |
|
$ |
11,818 |
|
|
100.0 |
% |
|
$ |
9,906 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
||||||
Operating income and operating margin |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
2,176 |
|
|
51.4 |
% |
|
$ |
2,279 |
|
|
54.2 |
% |
Analytical Instruments |
|
|
301 |
|
|
19.8 |
% |
|
|
272 |
|
|
19.6 |
% |
Specialty Diagnostics |
|
|
353 |
|
|
23.9 |
% |
|
|
428 |
|
|
26.5 |
% |
Laboratory Products and Biopharma Services |
|
|
620 |
|
|
11.4 |
% |
|
|
531 |
|
|
14.8 |
% |
Subtotal reportable segments |
|
|
3,450 |
|
|
29.2 |
% |
|
|
3,510 |
|
|
35.4 |
% |
|
|
|
|
|
|
|
|
|
||||||
Cost of revenues adjustments (a) |
|
|
(11 |
) |
|
-0.1 |
% |
|
|
(8 |
) |
|
-0.1 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
(7 |
) |
|
0.0 |
% |
|
|
(16 |
) |
|
-0.1 |
% |
Restructuring and other costs (c) |
|
|
(2 |
) |
|
0.0 |
% |
|
|
(14 |
) |
|
-0.1 |
% |
Amortization of acquisition-related intangible assets |
|
|
(609 |
) |
|
-5.2 |
% |
|
|
(423 |
) |
|
-4.3 |
% |
GAAP operating income |
|
$ |
2,821 |
|
|
23.9 |
% |
|
$ |
3,049 |
|
|
30.8 |
% |
(a) Adjusted results in 2022 and 2021 exclude charges for the sale of inventories revalued at the date of acquisition. |
(b) Adjusted results in 2022 and 2021 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions and charges/credits for changes in estimates of contingent acquisition consideration. |
(c) Adjusted results in 2022 and 2021 exclude restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Adjusted results in 2021 also exclude $13 of charges for compensation due to employees at recently acquired businesses at the date of acquisition. |
(d) Adjusted results in 2022 and 2021 exclude net gains/losses on investments and losses on the early extinguishment of debt. |
(e) Adjusted provision for income taxes in 2022 and 2021 excludes incremental tax impacts for the pre-tax reconciling items between GAAP and adjusted net income and incremental tax impacts as a result of tax rate changes. |
Note: |
Consolidated depreciation expense is $250 and $198 in 2022 and 2021, respectively. |
| Organic and Core organic revenue growth |
|
Three months ended |
|
|
April 2, 2022 |
Revenue growth |
|
19 % |
Acquisitions |
|
18 % |
Currency translation |
|
-2 % |
Organic revenue growth |
|
3 % |
COVID-19 testing revenue |
|
-12 % |
Contribution of PPD to Core organic revenue growth (a) |
|
1 % |
Core organic revenue growth |
|
16 % |
(a) Adjustment to include the contribution of PPD to Core organic revenue growth as though the acquisition had occurred on January 1, 2021. |
||
|
||
Note: |
||
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
||
| Condensed Consolidated Balance Sheet (unaudited) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
April 2, |
|
December 31, |
||||
(In millions) |
|
2022 |
|
2021 |
||||
|
|
|
|
|
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
2,752 |
|
|
$ |
4,477 |
|
Accounts receivable, net |
|
|
7,889 |
|
|
7,977 |
||
Inventories |
|
|
5,483 |
|
|
|
5,051 |
|
Other current assets |
|
|
2,652 |
|
|
|
2,608 |
|
Total current assets |
|
|
18,776 |
|
|
|
20,113 |
|
Property, plant and equipment, net |
|
|
8,448 |
|
|
|
8,333 |
|
Acquisition-related intangible assets, net |
|
|
19,378 |
|
|
|
20,113 |
|
Other assets |
|
|
4,424 |
|
|
|
4,640 |
|
Goodwill |
|
|
41,721 |
|
|
|
41,924 |
|
Total assets |
|
$ |
92,747 |
|
|
$ |
95,123 |
|
|
|
|
|
|
||||
Liabilities, redeemable noncontrolling interest and equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Short-term obligations and current maturities of long-term obligations |
|
$ |
1,866 |
|
|
$ |
2,537 |
|
Other current liabilities |
|
|
10,204 |
|
|
|
10,899 |
|
Total current liabilities |
|
|
12,070 |
|
|
|
13,436 |
|
Other long-term liabilities |
|
|
8,157 |
|
|
|
8,377 |
|
Long-term obligations |
|
|
31,389 |
|
|
|
32,333 |
|
Redeemable noncontrolling interest |
|
|
113 |
|
|
|
122 |
|
Total equity |
|
|
41,018 |
|
|
|
40,855 |
|
Total liabilities, redeemable noncontrolling interest and equity |
|
$ |
92,747 |
|
|
$ |
95,123 |
|
Condensed Consolidated Statement of Cash Flows (unaudited) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
Three months ended |
||||||
|
|
April 2, |
|
April 3, |
||||
(In millions) |
|
2022 |
|
2021 |
||||
|
|
|
|
|
||||
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
2,220 |
|
|
$ |
2,337 |
|
|
|
|
|
|
||||
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
859 |
|
|
|
621 |
|
Change in deferred income taxes |
|
|
(339 |
) |
|
|
24 |
|
Other non-cash expenses, net |
|
|
337 |
|
|
|
317 |
|
Changes in assets and liabilities, excluding the effects of acquisitions |
|
|
(875 |
) |
|
|
(1,321 |
) |
Net cash provided by operating activities |
|
|
2,202 |
|
|
|
1,978 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Acquisitions, net of cash acquired |
|
|
(40 |
) |
|
|
(1,343 |
) |
Purchases of property, plant and equipment |
|
|
(640 |
) |
|
|
(628 |
) |
Proceeds from sale of property, plant and equipment |
|
|
2 |
|
|
|
5 |
|
Other investing activities, net |
|
|
8 |
|
|
|
(32 |
) |
Net cash used in investing activities |
|
|
(670 |
) |
|
|
(1,998 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Repayment of debt |
|
|
(375 |
) |
|
|
(2,803 |
) |
Net proceeds from issuance of commercial paper |
|
|
626 |
|
|
|
— |
|
Repayment of commercial paper |
|
|
(1,259 |
) |
|
|
— |
|
Purchases of company common stock |
|
|
(2,000 |
) |
|
|
(2,000 |
) |
Dividends paid |
|
|
(103 |
) |
|
|
(87 |
) |
Net proceeds from issuance of company common stock under employee stock plans |
|
|
2 |
|
|
|
20 |
|
Other financing activities, net |
|
|
(36 |
) |
|
|
20 |
|
Net cash used in financing activities |
|
|
(3,145 |
) |
|
|
(4,850 |
) |
|
|
|
|
|
||||
Exchange rate effect on cash |
|
|
(99 |
) |
|
|
137 |
|
Decrease in cash, cash equivalents and restricted cash |
|
|
(1,712 |
) |
|
|
(4,733 |
) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
4,491 |
|
|
|
10,336 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
2,779 |
|
|
$ |
5,603 |
|
|
|
|
|
|
||||
|
|
|
|
|
||||
Free cash flow (non-GAAP measure) |
|
$ |
1,564 |
|
|
$ |
1,355 |
|
Notes: |
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
|
Supplemental Information Regarding Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired businesses and the effects of currency translation. We also report Core organic revenue growth, which is reported revenue growth including the impact of PPD revenue, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions other than PPD and currency translation. We calculate period-to-period Core organic revenue growth by adding to the baseline period PPD’s pre-acquisition revenues from such period. We report these measures because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions, foreign currency translation and/or COVID-19 testing on revenues. In particular, given PPD’s significance relative to our existing businesses, management believes it is appropriate to also present information on a basis that includes PPD pre-acquisition revenues in order to demonstrate the impact PPD has on our current growth profile. Core organic revenue growth amounts are not necessarily indicative of the combined results of operations that would have been realized had the PPD acquisition occurred on January 1, 2021. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
We report free cash flow, which is operating cash flow, excluding net capital expenditures to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.
The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.
УОЛТЕМ, Массачусетс.-- (BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), мировой лидер в области обслуживания науки, сегодня сообщила о своих финансовых результатах за первый квартал, закончившийся 2 апреля 2022 года.
Основные моменты первого квартала 2022 года
“Мы очень рады показать еще один квартал отличных результатов”, - сказал Марк Н. Каспер, председатель, президент и главный исполнительный директор Thermo Fisher Scientific. “Мы начали год с большой динамики, реализуя нашу проверенную стратегию роста и продолжая оставаться надежным партнером для наших клиентов. Наш бизнес по клиническим исследованиям PPD работает очень хорошо, интеграция проходит гладко, и мы еще больше рады возможностям, которые у нас есть, чтобы еще больше способствовать успеху наших фармацевтических и биотехнологических клиентов ”.
Каспер добавил: “Высокие результаты нашей команды в первом квартале позволяют нам провести еще один выдающийся год”.
Первый квартал 2022 года
Выручка за квартал выросла на 19% до 11,82 миллиарда долларов в 2022 году. Органический рост выручки составил 3%, приобретения увеличили выручку на 18%, а пересчет валюты снизил выручку на 2%. Основной органический рост составил 16%. Доход от тестирования на COVID-19 составил 1,68 миллиарда долларов.
Результаты по прибыли по ОПБУ
Разводненная прибыль на акцию по ОПБУ в первом квартале 2022 года составила 5,61 доллара против 5,88 доллара в том же квартале прошлого года. Операционная прибыль по ОПБУ за первый квартал 2022 года составила 2,82 миллиарда долларов по сравнению с 3,05 миллиарда долларов в предыдущем квартале. Операционная маржа по GAAP составила 23,9% по сравнению с 30,8% в первом квартале 2021 года.
Результаты прибыли, не связанные с ОПБУ
Скорректированная прибыль на акцию в первом квартале 2022 года составила 7,25 доллара против 7,21 доллара в первом квартале 2021 года. Скорректированный операционный доход за первый квартал 2022 года составил 3,45 миллиарда долларов по сравнению с 3,51 миллиарда долларов в первом квартале 2021 года. Скорректированная операционная маржа составила 29,2% по сравнению с 35,4% в первом квартале 2021 года.
Ежегодное руководство на 2022 год
Компания представит обновленные финансовые рекомендации на 2022 год во время телефонной конференции по доходам сегодня утром в 8:30 утра по восточному дневному времени.
Использование финансовых показателей, не относящихся к ОПБУ
Скорректированная прибыль на акцию, скорректированная чистая прибыль, скорректированный операционный доход, скорректированная операционная маржа, свободный денежный поток, органический рост выручки и основной органический рост выручки - это показатели, не относящиеся к GAAP, которые исключают определенные статьи, подробные после таблиц, которые сопровождают этот пресс-релиз, под заголовком "Дополнительная информация о финансовых показателях, не относящихся к GAAP". Сверка финансовых показателей GAAP с финансовыми показателями, не относящимися к GAAP, приведена в таблицах, прилагаемых к настоящему пресс-релизу.
Конференц-связь
Thermo Fisher Scientific проведет селекторное совещание по доходам сегодня, 28 апреля, в 8:30 утра по восточному дневному времени. Чтобы прослушать, наберите (844) 200-6205 в пределах США или (929) 526-1599 за пределами США. Код доступа - 310385. Вы также можете прослушать звонок в прямом эфире на нашем веб-сайте, www.thermofisher.com , нажав на кнопку ”Инвесторы". Вы найдете этот пресс-релиз, включая сопроводительную сверку финансовых показателей, не относящихся к GAAP, и соответствующую информацию, в этом разделе нашего веб-сайта в разделе “Финансовые показатели”. Аудиоархив звонка будет доступен в разделе “Новости и события” до пятницы, 13 мая 2022 года.
Об Thermo Fisher Scientific
Thermo Fisher Scientific Inc. является мировым лидером в области обслуживания науки с годовым доходом около 40 миллиардов долларов. Наша миссия состоит в том, чтобы дать возможность нашим клиентам сделать мир более здоровым, чистым и безопасным. Независимо от того, ускоряют ли наши клиенты исследования в области естественных наук, решают сложные аналитические задачи, повышают производительность в своих лабораториях, улучшают здоровье пациентов с помощью диагностики или разрабатывают и производят методы лечения, меняющие жизнь, мы здесь, чтобы поддержать их. Наша глобальная команда обеспечивает непревзойденное сочетание инновационных технологий, удобства покупок и фармацевтических услуг с помощью наших ведущих в отрасли брендов, включая Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon и PPD. Для получения дополнительной информации, пожалуйста, посетите www.thermofisher.com .
Заявление о безопасной гавани
Нижеследующее представляет собой заявление “Безопасной гавани” в соответствии с Законом о реформе судебных разбирательств по частным ценным бумагам 1995 года: Этот пресс-релиз содержит прогнозные заявления, которые связаны с рядом рисков и неопределенностей. Важные факторы, которые могут привести к тому, что фактические результаты будут существенно отличаться от тех, которые указаны в прогнозных заявлениях, включают риски и неопределенности, связанные с: продолжительностью и серьезностью пандемии COVID-19; необходимостью разработки новых продуктов и адаптации к значительным технологическим изменениям; реализацией стратегий улучшения роста; общими экономическими условиями и связанные с этим неопределенности; зависимость от политики капитальных затрат клиентов и политики государственного финансирования; влияние экономических и политических условий и колебаний валютных курсов на международные операции; использование и защита интеллектуальной собственности; влияние изменений в правительственных нормативных актах; любое стихийное бедствие, кризис общественного здравоохранения или другое катастрофическое событие; и влияние законов и нормативных актов, регулирующих государственные контракты, а также возможность того, что ожидаемые выгоды, связанные с недавними или предстоящими приобретениями, могут материализоваться не так, как ожидалось. Дополнительные важные факторы, которые могут привести к тому, что фактические результаты будут существенно отличаться от тех, которые указаны в таких прогнозных заявлениях, изложены в нашем последнем годовом отчете по форме 10-K, который находится в SEC и доступен в разделе “Инвесторы” нашего веб-сайта под заголовком “Заявки SEC.” Хотя мы можем принять решение обновить прогнозные заявления в какой-то момент в будущем, мы специально отказываемся от каких-либо обязательств делать это, даже если оценки изменятся, и, следовательно, вам не следует полагаться на эти прогнозные заявления как на отражение наших взглядов на любую дату после сегодняшнего дня.
Condensed Consolidated Statement of Income (unaudited) |
||||||||||||||
|
|
Three months ended |
||||||||||||
|
|
April 2, |
|
% of |
|
April 3, |
|
% of |
||||||
(In millions except per share amounts) |
|
2022 |
|
Revenues |
|
2021 |
|
Revenues |
||||||
Revenues |
|
$ |
11,818 |
|
|
|
|
$ |
9,906 |
|
|
|
||
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
Cost of revenues (a) |
|
|
6,214 |
|
|
52.6 |
% |
|
|
4,557 |
|
|
46.0 |
% |
Selling, general and administrative expenses (b) |
|
|
1,808 |
|
|
15.3 |
% |
|
|
1,543 |
|
|
15.6 |
% |
Amortization of acquisition-related intangible assets |
|
|
609 |
|
|
5.2 |
% |
|
|
423 |
|
|
4.3 |
% |
Research and development expenses |
|
|
364 |
|
|
3.1 |
% |
|
|
320 |
|
|
3.2 |
% |
Restructuring and other costs (c) |
|
|
2 |
|
|
0.0 |
% |
|
|
14 |
|
|
0.1 |
% |
|
|
|
8,997 |
|
|
76.1 |
% |
|
|
6,857 |
|
|
69.2 |
% |
Operating income |
|
|
2,821 |
|
|
23.9 |
% |
|
|
3,049 |
|
|
30.8 |
% |
Interest income |
|
|
18 |
|
|
|
|
|
12 |
|
|
|
||
Interest expense |
|
|
(136 |
) |
|
|
|
|
(125 |
) |
|
|
||
Other income/(expense) (d) |
|
|
(163 |
) |
|
|
|
|
(183 |
) |
|
|
||
Income before income taxes |
|
|
2,540 |
|
|
|
|
|
2,753 |
|
|
|
||
Provision for income taxes (e) |
|
|
(301 |
) |
|
|
|
|
(416 |
) |
|
|
||
Equity in earnings/(losses) of unconsolidated entities |
|
|
(19 |
) |
|
|
|
|
— |
|
|
|
||
Net income |
|
|
2,220 |
|
|
|
|
|
2,337 |
|
|
|
||
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
5 |
|
|
|
|
|
— |
|
|
|
||
Net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
2,215 |
|
|
18.7 |
% |
|
$ |
2,337 |
|
|
23.6 |
% |
|
|
|
|
|
|
|
|
|
||||||
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
$ |
5.66 |
|
|
|
|
$ |
5.93 |
|
|
|
||
Diluted |
|
$ |
5.61 |
|
|
|
|
$ |
5.88 |
|
|
|
||
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
|
392 |
|
|
|
|
|
394 |
|
|
|
||
Diluted |
|
|
395 |
|
|
|
|
|
397 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
GAAP operating income |
|
$ |
2,821 |
|
|
23.9 |
% |
|
$ |
3,049 |
|
|
30.8 |
% |
Cost of revenues adjustments (a) |
|
|
11 |
|
|
0.1 |
% |
|
|
8 |
|
|
0.1 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
7 |
|
|
0.0 |
% |
|
|
16 |
|
|
0.1 |
% |
Restructuring and other costs (c) |
|
|
2 |
|
|
0.0 |
% |
|
|
14 |
|
|
0.1 |
% |
Amortization of acquisition-related intangible assets |
|
|
609 |
|
|
5.2 |
% |
|
|
423 |
|
|
4.3 |
% |
Adjusted operating income (non-GAAP measure) |
|
$ |
3,450 |
|
|
29.2 |
% |
|
$ |
3,510 |
|
|
35.4 |
% |
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
GAAP net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
2,215 |
|
|
|
|
$ |
2,337 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
11 |
|
|
|
|
|
8 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
7 |
|
|
|
|
|
16 |
|
|
|
||
Restructuring and other costs (c) |
|
|
2 |
|
|
|
|
|
14 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
609 |
|
|
|
|
|
423 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
167 |
|
|
|
|
|
197 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
(169 |
) |
|
|
|
|
(130 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
19 |
|
|
|
|
|
— |
|
|
|
||
Adjusted net income (non-GAAP measure) |
|
$ |
2,861 |
|
|
|
|
$ |
2,865 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
|
$ |
5.61 |
|
|
|
|
$ |
5.88 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
0.03 |
|
|
|
|
|
0.02 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
0.02 |
|
|
|
|
|
0.04 |
|
|
|
||
Restructuring and other costs (c) |
|
|
0.01 |
|
|
|
|
|
0.04 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
1.54 |
|
|
|
|
|
1.06 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
0.42 |
|
|
|
|
|
0.50 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
(0.43 |
) |
|
|
|
|
(0.33 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
0.05 |
|
|
|
|
|
0.00 |
|
|
|
||
Adjusted EPS (non-GAAP measure) |
|
$ |
7.25 |
|
|
|
|
$ |
7.21 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
|
||||||
GAAP net cash provided by operating activities |
|
$ |
2,202 |
|
|
|
|
$ |
1,978 |
|
|
|
||
Purchases of property, plant and equipment |
|
|
(640 |
) |
|
|
|
|
(628 |
) |
|
|
||
Proceeds from sale of property, plant and equipment |
|
|
2 |
|
|
|
|
|
5 |
|
|
|
||
Free cash flow (non-GAAP measure) |
|
$ |
1,564 |
|
|
|
|
$ |
1,355 |
|
|
|
||
Segment data |
|
Three months ended |
||||||||||||
|
|
April 2, |
|
% of |
|
April 3, |
|
% of |
||||||
(In millions) |
|
2022 |
|
Revenues |
|
2021 |
|
Revenues |
||||||
|
|
|
|
|
|
|
|
|
||||||
Revenues |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
4,231 |
|
|
35.8 |
% |
|
$ |
4,203 |
|
|
42.4 |
% |
Analytical Instruments |
|
|
1,518 |
|
|
12.8 |
% |
|
|
1,387 |
|
|
14.0 |
% |
Specialty Diagnostics |
|
|
1,482 |
|
|
12.5 |
% |
|
|
1,615 |
|
|
16.3 |
% |
Laboratory Products and Biopharma Services |
|
|
5,442 |
|
|
46.0 |
% |
|
|
3,597 |
|
|
36.3 |
% |
Eliminations |
|
|
(855 |
) |
|
-7.1 |
% |
|
|
(896 |
) |
|
-9.0 |
% |
Consolidated revenues |
|
$ |
11,818 |
|
|
100.0 |
% |
|
$ |
9,906 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
||||||
Operating income and operating margin |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
2,176 |
|
|
51.4 |
% |
|
$ |
2,279 |
|
|
54.2 |
% |
Analytical Instruments |
|
|
301 |
|
|
19.8 |
% |
|
|
272 |
|
|
19.6 |
% |
Specialty Diagnostics |
|
|
353 |
|
|
23.9 |
% |
|
|
428 |
|
|
26.5 |
% |
Laboratory Products and Biopharma Services |
|
|
620 |
|
|
11.4 |
% |
|
|
531 |
|
|
14.8 |
% |
Subtotal reportable segments |
|
|
3,450 |
|
|
29.2 |
% |
|
|
3,510 |
|
|
35.4 |
% |
|
|
|
|
|
|
|
|
|
||||||
Cost of revenues adjustments (a) |
|
|
(11 |
) |
|
-0.1 |
% |
|
|
(8 |
) |
|
-0.1 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
(7 |
) |
|
0.0 |
% |
|
|
(16 |
) |
|
-0.1 |
% |
Restructuring and other costs (c) |
|
|
(2 |
) |
|
0.0 |
% |
|
|
(14 |
) |
|
-0.1 |
% |
Amortization of acquisition-related intangible assets |
|
|
(609 |
) |
|
-5.2 |
% |
|
|
(423 |
) |
|
-4.3 |
% |
GAAP operating income |
|
$ |
2,821 |
|
|
23.9 |
% |
|
$ |
3,049 |
|
|
30.8 |
% |
(a) Adjusted results in 2022 and 2021 exclude charges for the sale of inventories revalued at the date of acquisition. |
(b) Adjusted results in 2022 and 2021 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions and charges/credits for changes in estimates of contingent acquisition consideration. |
(c) Adjusted results in 2022 and 2021 exclude restructuring and other costs consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Adjusted results in 2021 also exclude $13 of charges for compensation due to employees at recently acquired businesses at the date of acquisition. |
(d) Adjusted results in 2022 and 2021 exclude net gains/losses on investments and losses on the early extinguishment of debt. |
(e) Adjusted provision for income taxes in 2022 and 2021 excludes incremental tax impacts for the pre-tax reconciling items between GAAP and adjusted net income and incremental tax impacts as a result of tax rate changes. |
Note: |
Consolidated depreciation expense is $250 and $198 in 2022 and 2021, respectively. |
| Organic and Core organic revenue growth |
|
Three months ended |
|
|
April 2, 2022 |
Revenue growth |
|
19 % |
Acquisitions |
|
18 % |
Currency translation |
|
-2 % |
Organic revenue growth |
|
3 % |
COVID-19 testing revenue |
|
-12 % |
Contribution of PPD to Core organic revenue growth (a) |
|
1 % |
Core organic revenue growth |
|
16 % |
(a) Adjustment to include the contribution of PPD to Core organic revenue growth as though the acquisition had occurred on January 1, 2021. |
||
|
||
Note: |
||
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
||
| Condensed Consolidated Balance Sheet (unaudited) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
April 2, |
|
December 31, |
||||
(In millions) |
|
2022 |
|
2021 |
||||
|
|
|
|
|
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
2,752 |
|
|
$ |
4,477 |
|
Accounts receivable, net |
|
|
7,889 |
|
|
7,977 |
||
Inventories |
|
|
5,483 |
|
|
|
5,051 |
|
Other current assets |
|
|
2,652 |
|
|
|
2,608 |
|
Total current assets |
|
|
18,776 |
|
|
|
20,113 |
|
Property, plant and equipment, net |
|
|
8,448 |
|
|
|
8,333 |
|
Acquisition-related intangible assets, net |
|
|
19,378 |
|
|
|
20,113 |
|
Other assets |
|
|
4,424 |
|
|
|
4,640 |
|
Goodwill |
|
|
41,721 |
|
|
|
41,924 |
|
Total assets |
|
$ |
92,747 |
|
|
$ |
95,123 |
|
|
|
|
|
|
||||
Liabilities, redeemable noncontrolling interest and equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Short-term obligations and current maturities of long-term obligations |
|
$ |
1,866 |
|
|
$ |
2,537 |
|
Other current liabilities |
|
|
10,204 |
|
|
|
10,899 |
|
Total current liabilities |
|
|
12,070 |
|
|
|
13,436 |
|
Other long-term liabilities |
|
|
8,157 |
|
|
|
8,377 |
|
Long-term obligations |
|
|
31,389 |
|
|
|
32,333 |
|
Redeemable noncontrolling interest |
|
|
113 |
|
|
|
122 |
|
Total equity |
|
|
41,018 |
|
|
|
40,855 |
|
Total liabilities, redeemable noncontrolling interest and equity |
|
$ |
92,747 |
|
|
$ |
95,123 |
|
Condensed Consolidated Statement of Cash Flows (unaudited) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
Three months ended |
||||||
|
|
April 2, |
|
April 3, |
||||
(In millions) |
|
2022 |
|
2021 |
||||
|
|
|
|
|
||||
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
2,220 |
|
|
$ |
2,337 |
|
|
|
|
|
|
||||
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
859 |
|
|
|
621 |
|
Change in deferred income taxes |
|
|
(339 |
) |
|
|
24 |
|
Other non-cash expenses, net |
|
|
337 |
|
|
|
317 |
|
Changes in assets and liabilities, excluding the effects of acquisitions |
|
|
(875 |
) |
|
|
(1,321 |
) |
Net cash provided by operating activities |
|
|
2,202 |
|
|
|
1,978 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Acquisitions, net of cash acquired |
|
|
(40 |
) |
|
|
(1,343 |
) |
Purchases of property, plant and equipment |
|
|
(640 |
) |
|
|
(628 |
) |
Proceeds from sale of property, plant and equipment |
|
|
2 |
|
|
|
5 |
|
Other investing activities, net |
|
|
8 |
|
|
|
(32 |
) |
Net cash used in investing activities |
|
|
(670 |
) |
|
|
(1,998 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Repayment of debt |
|
|
(375 |
) |
|
|
(2,803 |
) |
Net proceeds from issuance of commercial paper |
|
|
626 |
|
|
|
— |
|
Repayment of commercial paper |
|
|
(1,259 |
) |
|
|
— |
|
Purchases of company common stock |
|
|
(2,000 |
) |
|
|
(2,000 |
) |
Dividends paid |
|
|
(103 |
) |
|
|
(87 |
) |
Net proceeds from issuance of company common stock under employee stock plans |
|
|
2 |
|
|
|
20 |
|
Other financing activities, net |
|
|
(36 |
) |
|
|
20 |
|
Net cash used in financing activities |
|
|
(3,145 |
) |
|
|
(4,850 |
) |
|
|
|
|
|
||||
Exchange rate effect on cash |
|
|
(99 |
) |
|
|
137 |
|
Decrease in cash, cash equivalents and restricted cash |
|
|
(1,712 |
) |
|
|
(4,733 |
) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
4,491 |
|
|
|
10,336 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
2,779 |
|
|
$ |
5,603 |
|
|
|
|
|
|
||||
|
|
|
|
|
||||
Free cash flow (non-GAAP measure) |
|
$ |
1,564 |
|
|
$ |
1,355 |
|
Notes: |
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
|
Дополнительная Информация О Финансовых Показателях, Не Относящихся К ОПБУ
В дополнение к финансовым показателям, подготовленным в соответствии с общепринятыми принципами бухгалтерского учета (GAAP), мы используем определенные финансовые показатели, не относящиеся к GAAP, такие как органический рост выручки, который представляет собой рост выручки, о котором сообщается, исключая влияние доходов от приобретенных предприятий и влияние пересчета валют. Мы также сообщаем об основном органическом росте выручки, который представляет собой рост выручки, включая влияние выручки от PPD, исключая влияние выручки от тестирования на COVID-19 и исключая влияние приобретений, отличных от PPD и пересчета валют. Мы рассчитываем базовый органический рост выручки от периода к периоду, добавляя к базовому периоду выручку PPD до приобретения за этот период. Мы сообщаем об этих мерах, поскольку руководство Thermo Fisher считает, что для понимания краткосрочных и долгосрочных финансовых тенденций компании инвесторы могут пожелать рассмотреть влияние приобретений, пересчета иностранной валюты и / или тестирования на COVID-19 на доходы. В частности, учитывая важность PPD по отношению к нашим существующим предприятиям, руководство считает целесообразным также представить информацию на основе, включающей доходы от PPD до приобретения, чтобы продемонстрировать влияние PPD на наш текущий профиль роста. Основные показатели органического роста выручки не обязательно отражают совокупные результаты операций, которые были бы реализованы, если бы приобретение PPD произошло 1 января 2021 года. Руководство Thermo Fisher использует эти показатели для прогнозирования и оценки операционных показателей компании, а также для сравнения доходов за текущие периоды с предыдущими периодами.
Мы сообщаем о скорректированном операционном доходе, скорректированной марже операционного дохода, скорректированной чистой прибыли и скорректированной прибыли на акцию. Мы считаем, что использование этих финансовых показателей, не относящихся к GAAP, в дополнение к финансовым показателям GAAP, помогает инвесторам лучше понять наши основные операционные результаты и будущие перспективы, в соответствии с тем, как руководство оценивает и прогнозирует основные операционные показатели компании, особенно при сравнении таких результатов с предыдущими периодами, прогнозами, а также к производительности наших конкурентов. Такие меры также используются руководством при принятии финансовых и операционных решений, а также в целях компенсации. Для расчета этих показателей мы исключаем, если применимо:
Мы сообщаем о свободном денежном потоке, который представляет собой операционный денежный поток, исключая чистые капитальные затраты, чтобы дать представление о способности продолжающихся операций генерировать денежные средства для использования в приобретениях и других инвестиционных и финансовых мероприятиях. Компания также использует этот показатель в качестве показателя силы компании. Свободный денежный поток не является показателем наличности, доступной для дискреционных расходов, поскольку у нас есть определенные недискреционные обязательства, такие как обслуживание долга, которые не вычитаются из этого показателя.
Thermo Fisher Scientific не предоставляет прогнозные финансовые показатели GAAP, поскольку мы не можем с достаточной уверенностью и без необоснованных усилий прогнозировать такие элементы, как сроки и объем будущих действий по реструктуризации и расходов, связанных с приобретением, а также прибыли или убытки от продажи недвижимости и бизнеса, досрочный выход из долг и исход судебного разбирательства. Сроки и количество этих статей являются неопределенными и могут иметь существенное значение для результатов Thermo Fisher Scientific, рассчитанных в соответствии с GAAP.
Финансовые показатели результатов деятельности и движения денежных средств Thermo Fisher Scientific, не относящиеся к GAAP, включенные в этот пресс-релиз, не должны рассматриваться как превосходящие или заменяющие результаты деятельности Thermo Fisher Scientific, подготовленные в соответствии с GAAP. Сверки таких финансовых показателей, не относящихся к GAAP, с наиболее непосредственно сопоставимыми финансовыми показателями GAAP приведены в таблицах выше.
Показать большеПоказать меньше
